Navigation Links
Lung Cancer Alliance Commends NCCN on Screening Guidelines
Date:3/14/2008

WASHINGTON, March 14 /PRNewswire-USNewswire/ -- Lung Cancer Alliance (LCA) called the new screening guidelines announced by the National Comprehensive Cancer Network (NCCN) "a positive step in the right direction that will encourage those at high risk for lung cancer to fully investigate their option of getting a CT scan."

LCA President Laurie Fenton Ambrose said that lung cancer will continue to kill more people each year than all the other major cancers combined until more at risk people realize the urgency of being diagnosed early.

Currently only 16% of lung cancer patients are being diagnosed at an early and curable stage.

To date only CT scanners can detect lung cancers early - a fact that no one disputes - but the statistical debate goes on.

Fenton Ambrose pointed out that similar statistical debates held up mammograms for years until Congress stepped in. Debates still rage over mammograms for women under the age of 50 and PSA testing for prostate cancer in men.

The debate carried into the NCCN meeting earlier this month and the panel reviewing lung cancer was unable to reach a consensus on routine CT scans. However, NCCN issued a compromise statement recommending that people at high risk for lung cancer should participate in a clinical trial on CT screening or go to a center with expertise in all areas of lung cancer diagnosis and treatment to discuss the potential risks and benefits of a screening CT.

"This is exactly what we have been saying for the past two years," said Fenton-Ambrose, "and we are pleased that NCCN takes this position as well."

The only national CT trial still accepting participants is the International Lung Cancer Early Action Program (I-ELCAP).

That program, which was launched in 1992, has scanned over 30,000 people at high risk for lung cancer in 26 states and 8 foreign countries. The results of its first 13 years were published in the New England Journal of Medicine in 2006 and showed that CT scanning could detect lung cancer at its earliest stages, and those treated promptly had 10-year survival rates of 92%.

Currently, without screening, the national 5-year survival rate for lung cancer is 15%.

In 2002, the National Cancer Institute began a trial comparing CT scans to chest x-rays and stopped recruitment two years later. Those patients will be followed until 2009 but results are not expected to be published until 2012.

"Another 850,000 people will die of lung cancer by that time. We cannot continue to ignore the rapid advances in imaging that can offer those at high risk the chance of an early diagnosis when the disease is still curable," she said.

Lung Cancer Alliance (http://www.LungCancerAlliance.org) is the only national non-profit organization dedicated exclusively to patient support and advocacy for those living with or at risk for lung cancer. Lung Cancer Alliance is committed to leading the movement to reverse decades of stigma and neglect by empowering those with or at risk for the disease, elevating awareness and changing health policy.

Media Contact:

Kay Cofrancesco

kay@lungcanceralliance.org

202-463-2080


'/>"/>
SOURCE Lung Cancer Alliance
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
2. Anti-Cancer Drug CYT997 Update
3. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
4. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
5. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
6. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
7. GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
8. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
9. Northwestern Memorial Study Tests Cancer Drug on Scleroderma Patients
10. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
11. Thomson Healthcare Cancer Profiler Used in Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced ... Market Prospects: Addressing Production Complexities Through Risk Management and ... ... Pipeline and Market Prospects: Overcoming Production Complexities Through Risk ... of the current trends in the global biosimilars market, ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ... their offering. ... for drug delivery technologies will rise from USD 20 Billion in ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... 25, 2017 , ... A recent report from the Wisconsin ... the 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools ... in student test score performance, the report’s limited analyses fail to provide answers ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... ... Chaudhary, MD is committed to providing the highest quality of spine care to all his ... with all my patients to alleviate possible future issues. I am pleased to have you ... and my trained staff will assist you in any way possible.” , Dr. Saad Chaudhary ...
(Date:4/25/2017)... ... 25, 2017 , ... Vetoquinol USA® , a world-class ... part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in ... immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair of ...
(Date:4/24/2017)... Nashville, TN (PRWEB) , ... April 24, 2017 , ... ... electrifying fans and transforming the quarterback position. The former overall number one pick in ... his professional football career. He holds the record for the most career rushing yards ...
Breaking Medicine News(10 mins):